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Scleroderma
Implications for 
Nursing Care
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Signs & Symptoms
Signs and symptoms of scleroderma 
vary based on the subset of the disease, 
but according to Dixit, Kalkur, Sattur, 
Bornstein, & Melton (2016), they most 
commonly include:
•Raynaud’s Phenomenon (one of the first 
signs)
•Finger swelling, stiffness, or digital 
ulcers
•Nailfold capillary changes
•Gastrointestinal reflux
•Fatigue
•Weight loss
•Musculoskeletal pain
•Extremity edema
•Skin thickening (usually most obvious 
sign)
Pathophysiology
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Significance of Pathophysiology
Scleroderma is not an inherited 
disease; however, a history of familial 
genetic autoimmune disorders is 
thought to predispose individuals to the 
development of the disease.  
Environmental factors such as exposure 
to vinyl chloride, silica, and some viral 
and bacterial infections are thought to 
trigger the onset of the disease.
Scleroderma is an autoimmune 
disease related to highly specific 
autoantibodies.  Anti-centromere 
antibodies are associated with limited 
cutaneous scleroderma.  
Antitopoisomerase antibodies are a 
characteristic of the diffuse cutaneous 
subset.  While anti-RNA polymerase III 
antibodies are also found in diffuse 
cutaneous disease, they are associated 
with the added risk of renal 
involvement.  Anti-Th/To antibodies are 
linked to the limited cutaneous form 
with pulmonary fibrosis and PM-SCL 
antibodies specify scleroderma with 
polymyositis and severe calcinosis.  The 
autoantibodies are used in confirming 
diagnosis, predicting disease subset, and 
potential organ involvement (Chighizola, 
Raschi, Cesana, Borghi, & Meroni, 2015).  
In conclusion, scleroderma is a rare disease but one associated with multiple 
complications and comorbidities.  Increased knowledge of the signs and symptoms, 
familial history of autoimmune disorders, subset identification, pathophysiological 
process, and current treatment options are vital in the diagnosis and management of 
scleroderma.  Ongoing research into better symptom management, improved prognosis, 
and possible cure are grounded in the pathological foundation of the disease.  Healthcare 
providers should be abreast on the latest research and best practices when delivering 
care to their patients effected by the disease. 
Otterbein University, Westerville, Ohio
Conclusion
Understanding the pathophysiological underlaying of scleroderma has 
significantly helped to identify individuals effected by the disease and label subsets.  
It has also aided in the development of possible treatments that could potentially 
delay the progression of the disease.  Most research focuses on the blockage of 
pathways and mediators that promote formation of fibroblasts.  Although 
experiments with mice have been successful, the same success has not been seen in 
humans. 
Antibody specificity is thought to 
affect organ manifestations and 
phenotype expression (Caetano, 
Nihtyanova, Harvey, Ong, & Denton, 
2016).  According to Mitra, et al. (2015), 
mediators in the pathophysiological 
process of scleroderma include: 
•Transforming growth factor-β (TGF-
β): contributes to overproduction of 
extracellular matrix proteins (ECM) by 
fibroblasts and promotes differentiation 
of dermal fibroblasts to myofibroblasts. 
•Platelet derived growth factor 
(PDGF): helps in overproduction of ECM 
by fibroblasts
Microvascular damage has been 
found to be an early indicator of the 
disease process.  Endothelial cells induce 
vascular cell adhesion molecule (VCAM)-
1 expression, produce multiple cytokines 
and chemokines, release vasoconstrictor 
endothelin-1, and participate in the 
remodeling of vascular structures 
(Eckes, Moinzadeh, Sengle, Hunzelmann, 
& Kreig, 2014).  Basement membrane 
thickening and duplication create 
narrowing of the lumen of capillaries 
which leads to loss of microvasculature.  
A cascade of events triggers the 
inflammatory response with fibrosis 
often a result. 
Caring for a patient struggling with the 
diagnosis of scleroderma sparks interest into 
the subject for those unfamiliar with the 
disease.  This presentation is provided to 
further increase knowledge on the topic.
Scleroderma, which generically means 
hardening of the skin, is a rare disease that 
causes fibrosis of connective tissue resulting in 
loss of effectiveness.  Sclerosis is a 
heterogenous, multisystem, multistage 
disorder noted by variable expression in its 
forms of presentation and progression of 
disease (Masi & Medsger, 2015).  
Scleroderma has two main subsets: 
localized and systemic.  Both subsets have 
different patterns in which the disease can 
follow.  Localized scleroderma is mostly mild, 
does not involve internal organs, and generally 
consists of localized areas of skin or muscle.  It 
can be morphea, which consists of waxy 
patches of skin; or linear, which involve a line 
of hardened waxy skin either on limbs or 
forehead.  Systemic sclerosis (SSc) can be 
diffuse or limited.  SSc can involve muscle, 
joints, skin, blood vessels, and internal organs 
such as heart, lungs, gastrointestinal tract, and 
the esophagus.
Scleroderma: What is it and why discuss it?
Skin and organ fibrosis are key 
manifestations with SSc and the fingers are 
always effected (Distler & Cozzio, 2016).  
The diffuse form of SSc is a more rapidly 
progressing subset of the disease in which it 
is more likely for internal organs to be 
involved.  Limited scleroderma is 
sometimes referred to as CREST syndrome, 
the name being an acronym for the five 
common features of the disease: calcinosis, 
Raynaud’s phenomenon, esophageal 
dysfunction, sclerodactyly, and 
telangiectasia.  SSc predominately affects 
women ages 20-50 years of age and is 
associated with increased morbidity and 
mortality rates (Baron, 2016).  Scleroderma 
has no known specific cause; however, it 
does involve an overproduction of collagen.  
Localized scleroderma is more frequent in 
children while systemic scleroderma is seen 
more in adults.  Although there are 
treatments for symptoms of sclerosis, there 
is no cure. 
Contact with a patient in a medical office 
demonstrates the following data: 
•25-year-old Caucasian female, no co-
morbidities known to date
•Complaining of joint swelling, decreased 
hand grip, nausea, and heartburn
•Familial history of hypertension, 
diabetes, and maternal rheumatoid arthritis
•Further investigation reveals: 
involuntary weight loss of 20 lbs. over last 2-
3 months, cold/numb feeling in fingers when 
in air-conditioned environment, and 
shortness of breath with exertion
•Physical exam reveals: palpable hard 
deposits around upper extremity joints, 
early developing finger flexion contractures, 
and noted flat red marks to areas on face
Tests ordered with suspicion of 
scleroderma diagnosis:
•Complete blood count (CBC) 
•Antinuclear antibodies (ANA) 
•Scl-70 antibody 
•Comprehensive metabolic panel (CMP) 
•Centromere antibody (ACA) 
•Pulmonary function tests (PFTs) 
•Chest x-ray
Follow-up tests show:
•CBC and CMP within normal limits 
•Positive ANA, ACA, and Scl-70
•Interstitial fibrosis noted on x-ray
•PFTs suggestive of fibrosis
Diagnosis: Limited scleroderma with 
pulmonary fibrosis
Presentation of Case
While pathological evidence and 
research continues to focus on remission 
of the disease, nursing care must continue 
to focus on management of symptoms for 
those currently effected.  Symptom 
management generally focuses on 
vasculopathy, autoimmunity, and tissue 
fibrosis.  According to McMahan and 
Wigley (2013), rituximab, tocilizumab and 
IVIG are common drugs used now; along 
with newer agents that have shown 
promise, including bortezomib, LPA-1 
antagonists, anti-CCN2 therapy, anti-IL-13 
and thrombin antagonists.  Vasodilators, 
corticosteroids, proton pump inhibitors, 
and angiotension-converting enzyme 
inhibitors are also used; along with pain 
management and physical therapy, 
depending on specific organ involvement.  
Although medicinal treatments have 
several options, non-pharmacological 
interventions are lacking.  Research into 
non-pharmacological supportive therapy 
is being promoted by committees, such as 
Scleroderma Patient-Centered 
Intervention Network (SPIN), to develop 
patient centered care programs (Thombs, 
et al., 2012). 
Figure 2: Pulmonary fibrosis on chest x-ray
Figure 1: Image of sclerodactyly
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